Proactive Investors - Run By Investors For Investors

PreveCeutical awarded default judgement on civil claim in British Columbia

The health sciences company received a judgement against JCN Capital Corp
judge's gavel
The company argued that the defendants failed to provide PreveCeutical with agreed-upon consulting services and subscription agreements

PreveCeutical Medical Inc (CSE:PREV) (OTCMKTS:PRVCF) obtained a default judgement in a Supreme Court of British Columbia civil case, the company announced Monday.

The health sciences company received a default judgement against JCN Capital Corp in connection with a case brought by PreveCeutical alleging fraudulent misrepresentation, breach of contract, conspiracy, unjust enrichment and breach of duty of honest performance.

READ: PreveCeutical gets default judgement in part of civil claim

The Vancouver-based company argued that the defendants failed to provide PreveCeutical with agreed-upon consulting services and subscription agreements.

"We are pleased to have received this third default judgement as it demonstrates that PreveCeutical is actively pursuing this action," said PreveCeutical Chairman and CEO Stephen Van Deventer in a statement.

The amount of damages and costs awarded to PreveCeutical are still being assessed by the court.

The company continues to pursue other civil cases in the courts, according to a statement.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

View full PREV profile View Profile

PreveCeutical Medical Inc Timeline

Related Articles

cancer cell
00:42
The San Diego-based company has developed a patented liquid biopsy technology called Target Selector the detects and isolates cancer biomarkers such as circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA)
Pictured is the company's myLotus test
May 15 2019
Here we take a closer look at testing firm Concepta PLC (LON:CPT)
An illustration of Ozop's BLIF technique
March 31 2019
A key area of focus for the West Palm Beach, Florida, company is development of balloon lumbar interbody fusion (BLIF) technology

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use